1. Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
- Author
-
Kamposioras, K., Mauri, D., Papadimitriou, K., Anthoney, A., Hindi, N., Petricevic, B., Dambrosio, M., Valachis, A., Kountourakis, P., Kopecky, J., Kuhar, C.G., Popovic, L., Chilingirova, N.P., Zarkavelis, G., de Mello, R.A., Plavetić, N.D., Christopoulos, C., Mostert, B. (Bianca), Goffin, J. R., Tzachanis, D., Saraireh, H.H., Ma, F, Pavese, I., Tolia, M., Kamposioras, K., Mauri, D., Papadimitriou, K., Anthoney, A., Hindi, N., Petricevic, B., Dambrosio, M., Valachis, A., Kountourakis, P., Kopecky, J., Kuhar, C.G., Popovic, L., Chilingirova, N.P., Zarkavelis, G., de Mello, R.A., Plavetić, N.D., Christopoulos, C., Mostert, B. (Bianca), Goffin, J. R., Tzachanis, D., Saraireh, H.H., Ma, F, Pavese, I., and Tolia, M.
- Abstract
Introduction: Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. Methods: We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. Results: By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. Conclusions: In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
- Published
- 2020
- Full Text
- View/download PDF